# Capricor Therapeutics
 (stock symbol: CAPR) Logo in transparent PNG format

## Capricor Therapeutics
 Logo large

### Capricor Therapeutics
 Logo large Download PNG (28.29 KB)

![Capricor Therapeutics
 Logo large Download PNG (28.29 KB)](/img/orig/CAPR_BIG-7ca20b72.png)

## Capricor Therapeutics
 Logo icon format

### Capricor Therapeutics
 Logo icon format Download PNG (64.04 KB)

![Capricor Therapeutics
 Logo icon format Download PNG (64.04 KB)](/img/orig/CAPR-1cc7e78a.png)

## About Capricor Therapeutics


Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

1. Website domain: capricor.com
2. Employees: 48
3. Marketcap: $98.29 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
